Royalty Pharma Announces that Alexander von Perfall Joins Management Team

NEW YORK, December 7 - Royalty Pharma is pleased to announce that Alexander von Perfall has
joined the company as Vice President, Investor Relations.

(Logo: www.newscom.com/cgi-bin/prnh/20061026/RPLOGO)

Alexander has 13 years of cross-border management advisory, strategic
planning and principal investment experience, most recently as co-founder and
Chief Network Officer of XTF, a start-up Exchange Traded Funds Ratings
Agency. He previously advised the International Finance Corporation/World
Bank Group on the syndication of media sector private equity investments.
Alexander started his career with Bertelsmann AG where he held various
management positions, culminating with a position as Director of Business
Development where he initiated and oversaw investments in a number of early
stage media and entertainment ventures. Alexander attended the Hoschchule St.
Gallen in Switzerland before obtaining a BA in Politics from the University
of San Francisco and an MBA from the New York University - Stern School of
Business.

"The addition of Alexander to our management team adds an important
element of investor relationship management," said Pablo Legorreta, Chief
Executive Officer of Royalty Pharma. "Alexander will play a key role in
Royalty Pharma's efforts to enhance its investor and key stakeholder strategy
and communication, including acting as a liaison between Royalty Pharma's
management team and equity and debt investors, the analyst community and
media representatives."

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring revenue-producing
intellectual property - principally royalty interests in marketed and late
stage biopharmaceutical products with approximately US$6 billion in assets.
Royalty Pharma currently owns a diversified portfolio of royalty interests in
several high- quality blockbuster biopharmaceutical products, including
Abbott's Humira(R), J&J/Merck's Remicade(R), Pfizer's Lyrica(R), Amgen's
Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R),
Truvada(R) and Atripla(R), and Celgene's Thalomid(R). Royalty Pharma has a
thirteen year history of providing value to holders of royalty interests,
including its US$700 million purchase of the Lyrica(R) royalty from
Northwestern University, its US$650 million purchase of the Remicade(R)
royalty from New York University, its US$700 million purchase of the
Humira(R) royalty from AstraZeneca plc following its acquisition of Cambridge
Antibody Technology, its joint US$525 million acquisition with Gilead
Sciences of Emory University's emtricitabine royalty interest and its
acquisitions of approximately 80% of Memorial Sloan Kettering's U.S. and
international royalty interests in Neupogen(R) and Neulasta(R) for over
US$400 million. For more information, go to www.royaltypharma.com.

    For additional information, please contact:
    Pablo Legorreta                         Alexander v. Perfall
    Chief Executive Officer                 VP, Investor Relations
    +1-212-883-2288                         +1-212-883-2298
    plegorreta@royaltypharma.com            aperfall@royaltypharma.com

More information on Royalty Pharma is available at www.royaltypharma.com.

Pablo Legorreta, Chief Executive Officer, +1-212-883-2288, plegorreta at royaltypharma.com; Alexander v. Perfall, VP, Investor Relations, +1-212-883-2298, aperfall at royaltypharma.com